191 related articles for article (PubMed ID: 29641325)
1. Host genetics contributes to the effectiveness of dendritic cell-based HIV immunotherapy.
Reis EC; da Silva LT; da Silva WC; Rios A; Duarte AJ; Oshiro TM; Crovella S; Pontillo A
Hum Vaccin Immunother; 2018; 14(8):1995-2002. PubMed ID: 29641325
[TBL] [Abstract][Full Text] [Related]
2. Host genomic HIV restriction factors modulate the response to dendritic cell-based treatment against HIV-1.
Pontillo A; Da Silva RC; Moura R; Crovella S
Hum Vaccin Immunother; 2014; 10(2):512-8. PubMed ID: 24240316
[TBL] [Abstract][Full Text] [Related]
3. DC immunotherapy in HIV-1 infection induces a major blood transcriptome shift.
de Goede AL; Andeweg AC; van den Ham HJ; Bijl MA; Zaaraoui-Boutahar F; van IJcken WF; Wilgenhof S; Aerts JL; Gruters RA; Osterhaus AD;
Vaccine; 2015 Jun; 33(25):2922-9. PubMed ID: 25913415
[TBL] [Abstract][Full Text] [Related]
4. Gene Expression Signatures Associated With Immune and Virological Responses to Therapeutic Vaccination With Dendritic Cells in HIV-Infected Individuals.
Thiébaut R; Hejblum BP; Hocini H; Bonnabau H; Skinner J; Montes M; Lacabaratz C; Richert L; Palucka K; Banchereau J; Lévy Y
Front Immunol; 2019; 10():874. PubMed ID: 31105698
[TBL] [Abstract][Full Text] [Related]
5. Challenges in dendritic cells-based therapeutic vaccination in HIV-1 infection Workshop in dendritic cell-based vaccine clinical trials in HIV-1.
García F; Routy JP
Vaccine; 2011 Sep; 29(38):6454-63. PubMed ID: 21791232
[TBL] [Abstract][Full Text] [Related]
6. HIV-1 Reservoir Dynamics after Vaccination and Antiretroviral Therapy Interruption Are Associated with Dendritic Cell Vaccine-Induced T Cell Responses.
Andrés C; Plana M; Guardo AC; Alvarez-Fernández C; Climent N; Gallart T; León A; Clotet B; Autran B; Chomont N; Gatell JM; Sánchez-Palomino S; García F
J Virol; 2015 Sep; 89(18):9189-99. PubMed ID: 26109727
[TBL] [Abstract][Full Text] [Related]
7. A therapeutic dendritic cell-based vaccine for HIV-1 infection.
García F; Climent N; Assoumou L; Gil C; González N; Alcamí J; León A; Romeu J; Dalmau J; Martínez-Picado J; Lifson J; Autran B; Costagliola D; Clotet B; Gatell JM; Plana M; Gallart T;
J Infect Dis; 2011 Feb; 203(4):473-8. PubMed ID: 21233310
[TBL] [Abstract][Full Text] [Related]
8. Dendritic cell-based human immunodeficiency virus vaccine.
Rinaldo CR
J Intern Med; 2009 Jan; 265(1):138-58. PubMed ID: 19093966
[TBL] [Abstract][Full Text] [Related]
9. Polymorphisms in innate immunity genes and patients response to dendritic cell-based HIV immuno-treatment.
Segat L; Brandão LAC; Guimarães RL; Pontillo A; Athanasakis E; de Oliveira RM; Arraes LC; de Lima Filho JL; Crovella S
Vaccine; 2010 Mar; 28(10):2201-2206. PubMed ID: 20056178
[TBL] [Abstract][Full Text] [Related]
10. HIV immunotherapy comes of age: implications for prevention, treatment and cure.
Routy JP; Mehraj V; Cao W
Expert Rev Clin Immunol; 2016; 12(2):91-4. PubMed ID: 26629806
[TBL] [Abstract][Full Text] [Related]
11. CUL5 and APOBEC3G Polymorphisms are Partially Implicated in HIV-1 Infection and Antiretroviral Therapy in a Brazilian Population.
da Silva RC; Coelho AVC; de Moura RR; Arraes LC; Brandão LAC; Guimarães RL; Crovella S
Curr HIV Res; 2017; 15(4):245-257. PubMed ID: 28302043
[TBL] [Abstract][Full Text] [Related]
12. HIV-Tat immunization induces cross-clade neutralizing antibodies and CD4(+) T cell increases in antiretroviral-treated South African volunteers: a randomized phase II clinical trial.
Ensoli B; Nchabeleng M; Ensoli F; Tripiciano A; Bellino S; Picconi O; Sgadari C; Longo O; Tavoschi L; Joffe D; Cafaro A; Francavilla V; Moretti S; Pavone Cossut MR; Collacchi B; Arancio A; Paniccia G; Casabianca A; Magnani M; Buttò S; Levendal E; Ndimande JV; Asia B; Pillay Y; Garaci E; Monini P;
Retrovirology; 2016 Jun; 13(1):34. PubMed ID: 27277839
[TBL] [Abstract][Full Text] [Related]
13. The Evolution of Dendritic Cell Immunotherapy against HIV-1 Infection: Improvements and Outlook.
Mohamed H; Miller V; Jennings SR; Wigdahl B; Krebs FC
J Immunol Res; 2020; 2020():9470102. PubMed ID: 32537473
[TBL] [Abstract][Full Text] [Related]
14. A new approach to an AIDS vaccine: creating antibodies to HIV vif will enable apobec3G to turn HIV-infection into a benign problem.
Jeffrey Fessel W
Med Hypotheses; 2005; 64(2):261-3. PubMed ID: 15607551
[TBL] [Abstract][Full Text] [Related]
15. Using Dendritic Cell-Based Immunotherapy to Treat HIV: How Can This Strategy be Improved?
da Silva LT; Santillo BT; de Almeida A; Duarte AJDS; Oshiro TM
Front Immunol; 2018; 9():2993. PubMed ID: 30619346
[TBL] [Abstract][Full Text] [Related]
16. Characterization of monocyte-derived dendritic cells used in immunotherapy for HIV-1-infected individuals.
da Silva LT; da Silva WC; de Almeida A; da Silva Reis D; Santillo BT; Rigato PO; da Silva Duarte AJ; Oshiro TM
Immunotherapy; 2018 Aug; 10(10):871-885. PubMed ID: 30073900
[TBL] [Abstract][Full Text] [Related]
17. Therapeutic immunization with human immunodeficiency virus type 1 (HIV-1) peptide-loaded dendritic cells is safe and induces immunogenicity in HIV-1-infected individuals.
Connolly NC; Whiteside TL; Wilson C; Kondragunta V; Rinaldo CR; Riddler SA
Clin Vaccine Immunol; 2008 Feb; 15(2):284-92. PubMed ID: 17942609
[TBL] [Abstract][Full Text] [Related]
18. Genome-wide scan in two groups of HIV-infected patients treated with dendritic cell-based immunotherapy.
Moura Rodrigues R; Plana M; Garcia F; Zupin L; Kuhn L; Crovella S
Immunol Res; 2016 Dec; 64(5-6):1207-1215. PubMed ID: 27704462
[TBL] [Abstract][Full Text] [Related]
19. Amplified antigen-specific immune responses in HIV-1 infected individuals in a double blind DNA immunization and therapy interruption trial.
Gudmundsdotter L; Wahren B; Haller BK; Boberg A; Edbäck U; Bernasconi D; Buttò S; Gaines H; Imami N; Gotch F; Lori F; Lisziewicz J; Sandström E; Hejdeman B
Vaccine; 2011 Jul; 29(33):5558-66. PubMed ID: 21300092
[TBL] [Abstract][Full Text] [Related]
20. A phase I/IIa immunotherapy trial of HIV-1-infected patients with Tat, Rev and Nef expressing dendritic cells followed by treatment interruption.
Allard SD; De Keersmaecker B; de Goede AL; Verschuren EJ; Koetsveld J; Reedijk ML; Wylock C; De Bel AV; Vandeloo J; Pistoor F; Heirman C; Beyer WE; Eilers PH; Corthals J; Padmos I; Thielemans K; Osterhaus AD; Lacor P; van der Ende ME; Aerts JL; van Baalen CA; Gruters RA
Clin Immunol; 2012 Mar; 142(3):252-68. PubMed ID: 22177848
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
